BCLI Brainstorm Cell Therapeutics Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

BCLI [NASD]

Brainstorm Cell Therapeutics Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	1.10%	Shs Outstand	28.42M	Perf Week	17.69%
Market Cap	355.59M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	0.00%	Shs Float	22.96M	Perf Month	43.15%
Income	-26.30M	PEG	-	EPS next Q	-0.26	Inst Own	12.30%	Short Float	13.75%	Perf Quarter	158.24%
Sales	-	P/S	-	EPS this Y	-52.20%	Inst Trans	87.42%	Short Ratio	5.01	Perf Half Y	203.46%
Book/sh	0.32	P/B	41.16	EPS next Y	38.60%	ROA	-255.20%	Target Price	13.50	Perf Year	209.88%
Cash/sh	0.54	P/C	24.52	EPS next 5Y	-	ROE	726.40%	52W Range	3.43 - 13.61	Perf YTD	207.71%
Dividend	-	P/FCF	-	EPS past 5Y	-9.40%	ROI	-	52W High	-3.23%	Beta	1.13
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-	Gross Margin	-	52W Low	283.97%	ATR	1.01
Employees	32	Current Ratio	1.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	72.74	Volatility	8.23% 10.10%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-18.80%	Profit Margin	-	Rel Volume	1.20	Prev Close	12.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 07 BMO	Payout	-	Avg Volume	630.18K	Price	13.17
Recom	2.00	SMA20	23.60%	SMA50	58.84%	SMA200	137.86%	Volume	753,361	Change	2.65%

Dec-19-16

Reiterated

Maxim Group

Buy

$5 → $6

Dec-22-15

Reiterated

Maxim Group

Buy

$14 → $5

Jul-09-20 09:10AM	BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimers Disease; Raising Valuation to $25/Share Zacks Small Cap Research
Jul-08-20 05:31AM	BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire
Jul-02-20 06:49AM	BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire +9.03%
Jul-01-20 08:50AM	BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga +13.13%
Jun-24-20 09:06AM	BrainStorm to study stem cell treatment in Alzheimer's patients Reuters
07:00AM	BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire
Jun-23-20 05:45AM	BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index PR Newswire
Jun-15-20 09:00AM	BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire +17.36%
Jun-11-20 07:28AM	BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire -6.54%
Jun-10-20 05:40AM	BCLI: ALS Association and I AM ALS Awards $500,000 Grant; Potential Inclusion in Russell 3000 Index Zacks Small Cap Research
Jun-09-20 06:00AM	The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study PR Newswire +8.75%
Jun-04-20 07:09PM	Hedge Funds Warming Up To Brainstorm Cell Therapeutics Inc. (BCLI) Insider Monkey
Jun-03-20 06:00AM	BrainStorm to Participate in BIO Digital 2020 PR Newswire
Jun-02-20 06:00AM	BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020 PR Newswire
May-27-20 07:25AM	BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research PR Newswire
May-18-20 06:06AM	Does The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Share Price Tend To Follow The Market? Simply Wall St. +10.23%
May-08-20 05:35AM	BCLI: The Countdown to Phase 3 ALS Data Begins Zacks Small Cap Research
May-07-20 06:30AM	BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update GlobeNewswire -12.31%
01:00AM	BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union GlobeNewswire
May-04-20 03:30AM	BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology GlobeNewswire
Apr-29-20 06:00AM	BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update GlobeNewswire
Apr-08-20 06:40AM	BCLI: $1.5M Grant from Israel Innovation Authority Zacks Small Cap Research
Apr-03-20 06:59AM	BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority GlobeNewswire
Apr-01-20 09:00AM	David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer GlobeNewswire
Mar-31-20 04:00AM	BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors GlobeNewswire
Mar-16-20 03:00AM	BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 GlobeNewswire -18.92%
Mar-06-20 09:25AM	BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share GlobeNewswire +12.20%
Feb-27-20 01:00AM	Fifth and Final Site Announced for BrainStorms Progressive Multiple Sclerosis Phase 2 Clinical Trial GlobeNewswire -7.52%
Feb-20-20 05:10AM	BCLI: Phase 3 ALS Results in 4Q20 Zacks Small Cap Research
Feb-18-20 07:00AM	BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 GlobeNewswire +22.67%
06:00AM	Brainstorm Cell Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-17-20 01:00AM	BrainStorms Chief Operating Officer to Present at Noble Capital Markets Sixteenth Annual Investor Conference GlobeNewswire
Feb-11-20 06:00AM	BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS GlobeNewswire +14.74%
Feb-10-20 01:00AM	BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update GlobeNewswire
Feb-04-20 04:45AM	BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference GlobeNewswire
Jan-29-20 04:00AM	BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn® GlobeNewswire
Jan-21-20 09:53AM	BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit GlobeNewswire
Jan-17-20 06:00AM	How Many Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jan-07-20 01:00AM	BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week GlobeNewswire
Jan-03-20 10:21AM	Weekly CFO Buys Highlight GuruFocus.com
Dec-19-19 05:00AM	NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue GlobeNewswire
Dec-18-19 05:00AM	BrainStorm Issues 2019 Letter to Shareholders GlobeNewswire
Dec-11-19 05:00AM	BrainStorm Selected as Buzz of BIO 2020 Winner GlobeNewswire
Nov-26-19 08:05AM	BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND GlobeNewswire
Nov-25-19 06:00AM	BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site GlobeNewswire
Nov-21-19 06:15AM	BCLI: Phase 3 ALS Trial Fully Enrolled; Phase 2 Results Published in Neurology Zacks Small Cap Research
Nov-20-19 07:00AM	BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology GlobeNewswire
Nov-18-19 06:32AM	Does Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Have A High Beta? Simply Wall St.
Nov-14-19 08:07AM	The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Benzinga
07:00AM	BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society GlobeNewswire
06:00AM	BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update GlobeNewswire
Nov-13-19 05:00AM	BrainStorm Announces Grant of a New Japanese Patent for NurOwn® GlobeNewswire
Nov-12-19 01:00AM	BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting GlobeNewswire
Nov-05-19 06:15AM	BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update GlobeNewswire
Oct-28-19 07:45AM	NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue GlobeNewswire
Oct-25-19 01:00AM	BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire
Oct-24-19 08:45AM	BrainStorm Cell Therapeutics President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 GlobeNewswire
Oct-23-19 01:00AM	BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit GlobeNewswire
Oct-11-19 01:00AM	BrainStorms NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled GlobeNewswire
Oct-07-19 08:04AM	BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform GlobeNewswire
Oct-02-19 06:45AM	BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting GlobeNewswire
Sep-27-19 04:00AM	BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development GlobeNewswire
Sep-19-19 09:19AM	Is Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Growing Too Fast? Simply Wall St.
Sep-09-19 01:00AM	BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer GlobeNewswire
Sep-06-19 01:50AM	BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress GlobeNewswire
Aug-16-19 10:30AM	BCLI: 170 Patients Enrolled in Phase 3 ALS Trial Zacks Small Cap Research
Aug-13-19 07:30AM	BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update GlobeNewswire
06:00AM	Brainstorm Cell Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-05-19 01:00AM	BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update GlobeNewswire
Jul-10-19 07:08AM	If You Had Bought Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Three Years Ago, You Could Pocket A 59% Gain Today Simply Wall St.
Jul-02-19 08:15AM	Third Clinical Site Initiated for BrainStorm Cell Therapeutics Phase 2 Progressive MS Study GlobeNewswire
May-31-19 01:00AM	BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting GlobeNewswire
May-30-19 01:00AM	BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study GlobeNewswire
May-28-19 01:00AM	BrainStorm Senior Management to Present at BIO 2019 GlobeNewswire
May-21-19 10:15AM	BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19 Zacks Small Cap Research
May-13-19 01:00AM	BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London GlobeNewswire
May-10-19 05:00PM	BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update GlobeNewswire
Apr-30-19 04:00AM	BrainStorms Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases GlobeNewswire
Apr-04-19 10:30AM	BCLI: Two Abstracts to be Presented at AAN Annual Meeting Zacks Small Cap Research
Mar-28-19 04:30AM	Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting GlobeNewswire
Mar-26-19 06:30AM	BrainStorm Announces Grant of an additional New European Patent for NurOwn® GlobeNewswire
Mar-18-19 10:26PM	Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement GlobeNewswire
Mar-15-19 10:50AM	BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS Zacks Small Cap Research
Mar-14-19 01:00AM	BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire
Mar-13-19 11:57AM	Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Simply Wall St.
Mar-12-19 07:47AM	The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga
Mar-07-19 04:00AM	BrainStorm to Host Business Update Conference Call GlobeNewswire
Feb-22-19 07:30AM	BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire
Feb-21-19 06:00AM	BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire
Feb-19-19 08:06AM	BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire
Feb-04-19 08:22AM	BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium GlobeNewswire
Jan-25-19 07:15AM	BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire
Jan-22-19 08:40AM	BrainStorm Granted Additional Patent for NurOwn® in Israel GlobeNewswire
Jan-11-19 12:05AM	BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA GlobeNewswire
Jan-07-19 01:30PM	BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis Zacks Small Cap Research
Jan-03-19 06:04AM	BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week GlobeNewswire
Dec-27-18 07:35AM	BrainStorm Issues 2018 Letter to Shareholders GlobeNewswire
Dec-26-18 01:00AM	BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial GlobeNewswire
Dec-17-18 07:34AM	FDA Accepts BrainStorms NurOwn® IND Application for Progressive Multiple Sclerosis GlobeNewswire

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Preetam	EVP, CFO and Treasurer	Dec 24	Buy	3.96	11,600	45,929	36,600	Dec 27 07:01 AM
Kern Ralph Dr.	COO and Chief Medical Officer	Dec 24	Buy	3.88	3,000	11,640	115,655	Dec 27 07:01 AM
Araya Arturo	Chief Commercial Officer	Dec 24	Buy	3.90	3,000	11,700	8,608	Dec 27 07:00 AM
ARBEL IRIT	Director	Aug 28	Option Exercise	2.25	13,332	29,997	169,165	Aug 30 05:02 PM
ARBEL IRIT	Director	Aug 28	Sale	3.67	13,332	48,891	155,833	Aug 30 05:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience